Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Journal: Lancet (London, England)
Published: March 29, 2024
CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 05, 2024
The MOTION study: a randomized, phase III study of vimseltinib for the treatment of tenosynovial giant cell tumor.
Journal: Future oncology (London, England)
Published: August 18, 2023
Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages.
Journal: Molecular cancer therapeutics
Published: April 29, 2021
Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design.
Journal: Future oncology (London, England)
Published: November 01, 2018
Showing 1-6 of 6
Last Updated: 09/26/2026